South KoreaHealthcare and life sciences2026 – ongoingGC Biopharma
RegulAItor regulatory-affairs assistant
GC Biopharma said RegulAItor reduced regulatory-change research from hours to within 30 minutes
Problem
Regulatory staff spent hours finding supporting evidence for changes to pharmaceutical authorizations.
Approach
GC Biopharma developed RegulAItor and used it in regulatory-affairs work. The chatbot drew on FDA guidance and internal authorization documents to help staff determine how to handle changes.
Results
within 30 minutestime to assemble support for authorization changes, previously several hours, according to GC
Takeaway
The reported time saving concerned gathering regulatory support. GC did not report faster regulatory approval.
Categories
- Industry
- Healthcare and life sciences
- Business function
- Finance, risk and legalInternal work and knowledge management
- Innovation type
- Process innovation
- AI technology
- Generative AIConversational and voice AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
[1]Energy Economy10 Jun 2026
GC described its subsidiary's operational regulatory chatbot. It said evidence-gathering work that previously took hours could finish within 30 minutes.
Full details are in the original sources.
Added 1 Nov 2026 · Updated 1 Nov 2026
